Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

Clinical Infectious Diseases

Volumn 45, Issue 12, 2007, Pages 1568-1575

  McGeer, Allison ^a,b   Green, Karen A ^a   Plevneshi, Agron ^a   Shigayeva, Altynay ^a   Siddiqi, Nilofar ^a   Raboud, Janet ^b,c   Low, Donald E ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; OSELTAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CANADA; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA; INTENSIVE CARE UNIT; INTERVIEW; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; VACCINATION; CLINICAL TRIAL; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ONTARIO; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38949197905     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523584     Document Type: Article

References (40)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
2. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 2004; 160:492-502.
3. Loughlin J, Poulios N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21:273-84.
4. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
5. Cooper NJ, Sutton AJ, Abrams KR, Wailoo K, Turner DA, Nichoson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235-42.
6. Monto AS. The role of antivirals in the control of influenza. Vaccine 2003; 21:1796-800.
7. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden FS. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
8. Monto AS,Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44(Suppl B):23-9.
9. Roberts A, Bitnun A, McGeer A, et al. Laboratory-confirmed influenza-associated hospitalizations among children in the metropolitanToronto and Peel region by active surveillance, 2004-2005. Can Commun Dis Rep 2006; 32:203-7.
10. Daneman N, McGeer A, Green K, Low DE; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432-8.
11. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-97.
12. Toronto Invasive Bacterial Diseases Network. Surveillance for laboratory-confirmed influenza requiring hospital admission in adults, metropolitan Toronto and Peel region, 2004-2005 influenza season. Can Commun Dis Rep 2005; 31:249-55.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
14. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2005-2006 season: an advisory committee statement. Can Commun Dis Rep 2006; 31:1-30.
15. Reyes F, Macey JF, Aziz S, et al. Influenza in Canada: 2005-6 season. Can Commun Dis Rep 2007; 33:21-41.
16. Bowles SB, Lee W, Simor AE, et al.; Oseltamivir Compassionate Use Program Group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.
17. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21:761-8.
18. Ison MG, Gnann JW Jr, Nagy-Agren S, et al.; NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8: 183-90.
19. Lee N, Chan P, Choi K, Hui D, Cockram C, Sung J. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501-8.
20. Aoki FY, Macleod MD, Paggiaro P, et al.; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
21. Gillissen A, Hoffken G. Early therapy with neuraminidase inhibitor oseltamivir maximized its efficacy in influenza treatment. Med Microbiol Immunol 2002; 191:165-8.
22. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol 2006; 80:7590-9.
23. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352-5.
24. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-6.
25. Johansen H, Sambell C, Zhao W. Flu shots - national and provincial/ territorial trends. Health Rep 2006; 17:43-8.
26. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-5.
27. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006:CD004876.
28. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:1769-75.
29. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31:72-9.
30. Xie L, Squires SG, Macey JF, et al. Infuenza in Canada: 2004/5 season. CCDR 2006; 32:57-74. Available at: http://www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/06pdf/cdr3206.pdf. Accessed 30 October 2007.
31. Reyes F, Macey JF, Aziz F, et al. Influenza in Canada: 2005-2006 season. CCDR 2007; 33:21-41. Available at: http://www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/07vol33/dr3303e.html. Accessed 30 October 2007.
32. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
33. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007; 167:354-60.
34. Poehling KA, Edwards KM, Weinberg GA, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31-40.
35. Ruest A, Michaud S, Deslandes S, Frost EH. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003; 41:3487-93.
36. Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31:1166-9.
37. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-7.
38. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
39. Kawai N, Ikematsu H, Iwaki N, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect 2007; 55:267-72.
40. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-44.